These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25374510)

  • 1. Nanobodies as modulators of inflammation: potential applications for acute brain injury.
    Rissiek B; Koch-Nolte F; Magnus T
    Front Cell Neurosci; 2014; 8():344. PubMed ID: 25374510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of nanobodies targeting GPCR.
    Zhang S; Fan Z; Liu J
    Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies: The Future of Antibody-Based Immune Therapeutics.
    Bathula NV; Bommadevara H; Hayes JM
    Cancer Biother Radiopharm; 2021 Mar; 36(2):109-122. PubMed ID: 32936001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A guide to: generation and design of nanobodies.
    Muyldermans S
    FEBS J; 2021 Apr; 288(7):2084-2102. PubMed ID: 32780549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
    Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
    Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobodies in cancer.
    Verhaar ER; Woodham AW; Ploegh HL
    Semin Immunol; 2021 Feb; 52():101425. PubMed ID: 33272897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.
    Mujić-Delić A; de Wit RH; Verkaar F; Smit MJ
    Trends Pharmacol Sci; 2014 May; 35(5):247-55. PubMed ID: 24690241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of nanobodies for therapeutic applications.
    Van Bockstaele F; Holz JB; Revets H
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
    Al-Baradie RS
    Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of nanobodies against rhGH expressed as sfGFP fusion protein.
    Abbady AQ; Al-Shemali R; Mir Assaad J; Murad H
    Gen Comp Endocrinol; 2014 Aug; 204():33-42. PubMed ID: 24859761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobodies that Neutralize HIV.
    Weiss RA; Verrips CT
    Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31370301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in nanobody and its application in diagnosis].
    Kong Q; Yao Y; Chen R; Lu S
    Sheng Wu Gong Cheng Xue Bao; 2014 Sep; 30(9):1351-61. PubMed ID: 25720150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 16. Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy.
    Jank L; Pinto-Espinoza C; Duan Y; Koch-Nolte F; Magnus T; Rissiek B
    Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.
    Wesolowski J; Alzogaray V; Reyelt J; Unger M; Juarez K; Urrutia M; Cauerhff A; Danquah W; Rissiek B; Scheuplein F; Schwarz N; Adriouch S; Boyer O; Seman M; Licea A; Serreze DV; Goldbaum FA; Haag F; Koch-Nolte F
    Med Microbiol Immunol; 2009 Aug; 198(3):157-74. PubMed ID: 19529959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
    Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
    J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies.
    Khodabakhsh F; Behdani M; Rami A; Kazemi-Lomedasht F
    Int Rev Immunol; 2018; 37(6):316-322. PubMed ID: 30741045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of Nanobodies.
    Muyldermans S
    Annu Rev Anim Biosci; 2021 Feb; 9():401-421. PubMed ID: 33233943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.